IND applications and FDA oversight of psychedelic clinical trials

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Researchers, sponsors, and institutions planning or running a psychedelic clinical trial who need to understand the FDA’s role and what an Investigational New Drug application involves.

The short answer

An Investigational New Drug application is the authorization a sponsor files with the FDA before giving an investigational drug to human participants in a clinical trial. Without an IND in effect, a study may not proceed. The FDA reviews the application to assess whether it is safe to expose people to the drug at the proposed dose, in the proposed population, under the proposed protocol, and it oversees the trial once it is underway through reporting requirements, inspections, and the authority to put a study on clinical hold. For psychedelics, the FDA has worked with sponsors including MAPS and COMPASS through the IND process, and it has issued guidance on certain trial design considerations specific to psychedelic-assisted therapies.

What an IND is and what it does

An IND is not a drug approval. It is permission to conduct the specific study described in the application, under the conditions set out in the submission, for research purposes. An IND in effect means the FDA has reviewed the application and has not placed the study on clinical hold within 30 days. The authorization covers the study protocol as submitted; changes to the protocol need to be reported to the FDA, and material changes require a protocol amendment. The IND stays open as long as the study continues, and the sponsor submits annual progress reports.

Who files an IND

An IND can be filed by a company, an academic institution, a researcher, or a government agency. A sponsor-investigator is a researcher who both sponsors and conducts the study. The obligations of the IND, including the safety reporting requirements and the protocol amendments, run to the sponsor. For a psychedelic trial, the sponsor is often a biotech company funding the research, but academic researchers running investigator-initiated trials file their own INDs and carry the sponsor obligations.

What the application contains

The IND includes three main categories of information. The first is the animal pharmacology and toxicology data that give the FDA a basis to assess whether human exposure is reasonably safe at the proposed starting dose. The second is the manufacturing information, which covers the composition and source of the drug, the controls on its production, and its stability. The third is the clinical protocol and the investigator information, describing the study design, the patient population, the dose and route, the endpoints, and the qualifications of the people running the study. An IND for a Phase 1 first-in-human study carries less clinical data than one for a Phase 3 pivotal trial.

The FDA’s review and the clinical-hold authority

The FDA has 30 days to review an initial IND and place it on clinical hold if it finds a problem. If no hold is issued, the study may proceed. A clinical hold stops enrollment or the whole study, and the sponsor has to address the FDA’s concerns before resuming. Common grounds for a hold include inadequate safety data, a protocol that puts participants at unreasonable risk, or deficiencies in the informed consent. The authority to put studies on hold gives the FDA practical oversight of ongoing research, not only initial review.

Safety reporting obligations

Once a study is underway, the sponsor must report safety events to the FDA. Unexpected serious adverse reactions that are reasonably related to the study drug go to the FDA quickly, on timelines that depend on whether the event is fatal or life-threatening. The sponsor also submits annual reports and must tell the FDA about findings from other studies that affect the risk-benefit picture. Psychedelic trials produce adverse events, including psychological distress and re-emerging psychiatric symptoms, that the sponsor characterizes and reports under these rules.

FDA guidance specific to psychedelic trials

The FDA has acknowledged that psychedelic-assisted therapy trials raise design questions that standard trial formats do not fully address, including how to blind participants and raters when the drug produces distinctive subjective effects, how to structure the therapy component, and how to define and measure outcomes. The agency has engaged with sponsors on these questions through the pre-IND meeting process and through guidance documents. A sponsor planning a psychedelic trial benefits from requesting a pre-IND meeting with the FDA to discuss the protocol before filing, because the agency’s feedback can prevent design problems that would be expensive to fix later.

Breakthrough Therapy designation and its effects

The FDA can designate a drug as a Breakthrough Therapy if preliminary evidence suggests it may offer a substantial improvement over existing treatment for a serious condition. Breakthrough Therapy designation gives the sponsor more intensive FDA guidance during development, including earlier interaction and a commitment to more frequent communication. COMPASS Pathways received Breakthrough Therapy designation for psilocybin in treatment-resistant depression, and that status shaped the development pathway for COMP360. Designation speeds development in practice by improving the quality of the FDA’s input; it does not lower the evidence standard for approval.

What the IND does not authorize

An IND authorizes the study described in the application, conducted by the listed investigators at the listed sites, for research purposes. It does not authorize providing the drug to people outside the study, using it in clinical practice, or making it commercially available. A participant who benefits from a drug in a trial still cannot access it outside the trial unless a separate authorization such as expanded access applies. What FDA approval does and does not mean for psychedelic treatments and Clinical trials vs. legal access programs: what’s the difference? cover those limits.

When public information may be enough

The FDA’s IND regulations, guidance documents, and the agency’s published correspondence with psychedelic sponsors are largely public. A researcher can learn the IND requirements and the safety-reporting obligations from those sources, and the agency’s psychedelic-specific guidance is available on its website. Understanding the process in general is achievable from public reading; assembling and submitting a specific IND is where expert regulatory help becomes necessary.

When you should speak with a lawyer or regulatory professional

A sponsor filing an IND for a psychedelic trial should work with regulatory professionals who know the FDA’s current thinking on trial design and safety reporting for this class of drugs, and legal counsel who can manage the obligations the IND creates. A pre-IND meeting with the FDA is often the single most useful early step, and preparing for it well requires knowing what the agency has said about similar protocols before. Drug development timelines and what FDA approval actually requires covers the longer path that begins with the IND.

You might also want to read

This article provides general legal information, not legal advice, and does not create an attorney-client relationship. Psychedelic law differs by state and changes over time. Consult a licensed attorney in your jurisdiction before acting on anything described here.